Press release - 2 Sept 2026
-
Press release - 2 Sept 2026
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody...
TEV'408 is also in Phase 1b testing for the treatment of vitiligo.
-
T #medicine shared this topic on
-
Press release - 2 Sept 2026
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody...
TEV'408 is also in Phase 1b testing for the treatment of vitiligo.
Great news - perhaps this can help those with refractory Celiac someday.
I'm wondering how they got people to volunteer for the trial, given the possibility of being placed in the placebo group.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better đź’—
Register Login